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Abstract: General anesthetic drugs interact with many receptors in the nervous system, but only a handful of these inter-
actions are critical for producing anesthesia. Over the last 20 years, neuropharmacologists have revealed that one of the 
most important target sites for general anesthetics is the GABAA receptor. In this review we will discuss what is known 
about anesthetic – GABAA receptor interactions.  
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INTRODUCTION 
  General anesthetics have been used to relieve pain and 
suffering in surgical patients for almost 170 years. Prior to 
their discovery, surgery was a traumatic and barbaric affair, 
yet  today,  it  is  accepted  as a routine and essential part of 
modern  medicine.  It  is  curious  therefore,  that  despite  the 
technological advances that have been made in perioperative 
medicine and surgical techniques, the pharmacologic thera-
peutics administered by anesthesiologists to render patients 
unconscious,  continue to be used without a precise under-
standing of how they generate the anesthetized state.  
  Fortunately, over the last two decades, the intensive use 
of the tools of modern molecular pharmacology and neuro-
science has enabled investigators to understand better than 
ever before how anesthetic chemicals can alter the function 
of the nervous system. In this review, we will carefully de-
fine what we mean by “anesthesia” and then we will focus 
on  how  the  currently  used  anesthetic  agents  modulate  the 
function of the GABAA receptor (GABAAR), the most abun-
dant fast inhibitory neurotransmitter receptor in the CNS.  
  At the outset, we would like to emphasize that this re-
view is neither historical nor is it exhaustive. We do not in-
tend to review the interaction of every drug used by anesthe-
siologists in the Operating Room, past or present, with every 
critical binding site in the body. The purpose of this review 
is to summarize some of the key findings that we feel have 
advanced our understanding of how the currently used gen-
eral anesthetic drugs interact with their neuronal targets. The 
history of anesthetic pharmacology is rich and has played a 
critical  role  in  our  understanding  of  the  anesthetized  state 
and the reader is encouraged to read previous reviews if they 
are interested in reviewing the action of disused anesthetics 
such  as  halothane,  chloroform  or  ether.  Neither  shall  we 
dwell on discarded theories of anesthetic action. It is the fer-
vent view of the authors that general anesthesia is no differ-
ent  from  any  other  pharmacological  process:  exogenously  
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administered drugs interact with key sites on  cellular pro-
teins in the body which results directly in the alteration in the 
function of these proteins, in the present case, neuronal pro-
teins that control how information is conveyed through the 
nervous system.  
  It is noteworthy that the study of general anesthesia as a 
whole, has not immediately lent itself to being accessible to 
traditional pharmacology; anesthesia is a clinical state where 
a myriad of behavioral endpoints are caused by a group of 
drugs  that  bear  no  physical  resemblance  to  one  another. 
Nevertheless,  it  appears  that  GABAARs  are  incredibly  ac-
commodating and possess several binding sites that interact 
with many of the currently used general anesthetics. Moreo-
ver, these interactions obey many of the basic principles of 
rational  pharmacology;  the  effects  of  drug  on  protein  are 
concentration dependent, they are subject to the “ceiling ef-
fect”, they are allosteric in nature, the effects are dependent 
on the temperature of the preparation, some compounds ex-
hibit stereoselectivity and depending on the anesthetic, they 
appear to modulate the efficacy and/or the apparent affinity 
of the receptor for its endogenous ligand.  
  In the following sections, we will define what we under-
stand to be  “general  anesthesia” and how anesthetic drugs 
interact with native and mutant GABAARs.  
WHAT IS GENERAL ANESTHESIA? 
  When  Oliver  Wendell  Holmes  first  coined  the  term 
anæsthesia in 1846, the word, which literally means a lack of 
sensation, was used to describe a patient who after inhaling 
ether vapor, underwent surgery without any apparent suffer-
ing. Widespread use of the technique and this term followed, 
describing a state where one or more chemicals were sys-
temically administered to “anesthetize” patients, permitting 
humane  surgery  to  occur.  Arguably  one  of  the  greatest 
breakthroughs in  medical history, it  is  interesting  that this 
essential  component  of  modern  medicine  has  developed 
without a rational theory consistent with modern pharmacol-
ogy  that  accounts  for  the  molecular  mechanisms  of  these 
drugs in the human body.  
  One reason for this is that after more than 160 years of 
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larly defines the anesthetized state. During general anesthe-
sia, a myriad of events occur in the body that alter motor 
responses,  cognition,  sensation  and  autonomic  control.  A 
patient will go from being anxious, to unconscious and im-
mobile and back to awake and in light of this, there contin-
ues to be a debate on which of these effects, or what combi-
nation of these effects are the critical determinants of general 
anesthesia.  
  The seminal work by Eger et al. [64], set the benchmark 
in understanding anesthetic actions for almost 50 years. The 
definition of the Minimum Alveolar  Concentration (MAC) 
places great emphasis on anesthetic induced immobility, as a 
read-out for sensation, and less emphasis on processes not 
directly linked to the sensation of acute pain and their asso-
ciated  motor  reflexes.  Subsequent  research  has  demon-
strated, perhaps not unsurprisingly, that the key sites in the 
nervous system that determine MAC are found in the spinal 
cord [3] and interestingly, may not be critically dependent on 
GABAARs [73]. Nevertheless, although MAC may not have 
revealed information on the cerebral sites of anesthetic ac-
tion and anesthetic actions on sensory processing, one of the 
great benefits of the MAC studies was to define a set of drug 
concentrations that are appropriate for use in in vitro studies 
on potential molecular targets, a giant leap forward for mo-
lecular  pharmacologists  interested  in  understanding  how 
these drugs induce anesthesia.  
  For many decades after the inception of general anesthe-
sia, through the lack of available drugs, it was usual for only 
one general anesthetic drug to be used to induce immobility, 
analgesia,  muscle relaxation, amnesia  and unconsciousness 
all at once. It turns out that anesthesia generated in this way 
was  a  dangerous  practice.  The  therapeutic  index  for  these 
early anesthetic drugs was in the low single digits. Modern 
anesthesia on the other hand makes use of much safer drugs 
with higher therapeutic indices and is very rarely achieved 
with  a  single  drug.  Anesthesiologists  several  devices  to 
measure a patient’s vital signs and actively balance cocktails 
of drug arrays, with the effect of one drug sparing the patient 
exposure  to  higher  concentrations  of  another  and  in  some 
cases,  making  use  of  the  synergistic  combination  of  some 
drug pairs [15, 23, 30, 61].  
  Therefore, to recap: under conditions of optimal monitor-
ing, sedation and anesthesia,  it  is possible for a patient to 
undergo surgery and have no recall of intra-operative events. 
With the safer drugs in clinical practice today, we acknowl-
edge that modest movements may persist if neuromuscular 
blockade is not employed yet the patient is senseless of their 
surroundings and surgery can be completed without any ad-
verse events. This satisfies the original definition of anesthe-
sia  –  no  sensation  accompanied  by  a  successful  surgery. 
Therefore,  a  review  of  the  current  neuropharmacology  
of  general  anesthetic  drugs  should  discuss  the  non-
immobilizing sedative drugs as well as general anesthetics. 
We acknowledge the important role benzodiazepines play in 
the perioperative setting but would like to point the reader to 
an accompanying review in this volume that extensively re-
views  the  interaction  of  benzodiazepines  with  GABAARs 
and the importance of the  these interactions for anxiolysis 
and sedation.  
THEORY OF GENERAL ANESTHETIC ACTION  
  At  the  cellular  level,  anesthetics  alter  the  behavior  of 
neurons, by interacting directly with a small number of ion 
channels. Under normal conditions, these specialized mem-
brane proteins are activated by chemical signals or changes 
in  the  membrane  environment.  Upon  activation,  channels 
change the electrical excitability of neurons by controlling 
the flow of depolarizing (excitatory) or hyperpolarizing (in-
hibitory) ions across the cell membrane via an ion channel 
that is integral with the receptor that senses the initial signal. 
General anesthetics primarily act by either enhancing inhibi-
tory signals or by blocking excitatory signals. It is important 
to note that none of the current clinical general anesthetics 
are selective for a single ion channel. At clinical concentra-
tions, every anesthetic modulates the function of two or more 
types of channels in the central nervous system. Thus, each 
different anesthetic agent alters neuronal activity by acting in 
differing degrees at multiple sites. 
GENERAL ANESTHETICS AND THEIR TARGETS 
  Currently, there are 5 inhalational and 5 intravenous an-
esthetics used to induce or maintain general anesthesia: Inha-
lational: Nitrous Oxide, Isoflurane, Sevoflurane, Desflurane 
and  Xenon.  Intravenous:  Propofol,  Etomidate,  Ketamine, 
Methohexital  and  Thiopental.  These  10  general  anesthetic 
drugs are often  accompanied by sedative benzodiazepines: 
midazolam, diazepam and lorazepam.  
  Of these 10 general anesthetics, ketamine, nitrous oxide 
and  xenon  inhibit  ionotropic  glutamate  receptors,  with  the 
strongest effects being seen on the NMDA receptor subtype. 
These anesthetics  also have  modest effects on many other 
receptors, including GABAARs, but their primary action is 
the blockade of NMDA receptors and will not be covered 
further in this review.  
  The other 7 general anesthetics and 3 sedatives share a 
common target and mechanism of action, they all enhance 
the function of GABAARs, the most abundant fast inhibitory 
neurotransmitter receptor in the CNS. These 7 general anes-
thetics also have a spectrum of modest to strong effects on 
other  ion  channels,  including  glycine  receptors,  neuronal 
nicotinic receptors, 5-HT3 receptors, glutamate receptors and 
the two pore potassium channels [1, 17], with each drug dif-
fering  in  its  array  of  effects,  but  in  order  to  focus  on  the 
GABAAR effects, the effects on these other ion channels will 
also not be considered further in this review.  
THE GABAA RECEPTOR  
Receptor Diversity and Anatomical Expression 
  Along with the nicotinic acetylcholine receptor (nAChR), 
the  glycine  receptor,  and  the  serotonin  type  3  (5-
hydroxytryptamine type 3) receptor, GABAARs are members 
of  the  Cys-loop  superfamily  of  ligand-gated  ion  channels. 
Each of these receptors is formed as a pentameric combina-
tion  of  transmembrane  polypeptide  subunits.  The  name  of 
the  superfamily  comes  from  the  characteristic  “cys-loop” 
found in all subunits, defined by a disulfide bond between 
two cysteine residues separated by 13 amino acid residues. 
Neurotransmitter  binding  sites  are  located  at  two  or  more 
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endogenous ligand binds between the α and β subunits. So 
far,  nineteen  genes  have  been  identified  for  GABAAR 
subunits (α1 – 6, β1 – 3, γ1 – 3, δ, ε, θ, π, ρ1 – 3)[62]. De-
spite  nearly  2.5  million  different  possible  permutations  of 
subunits, only nine different receptor configurations are une-
quivocally expressed in significant amounts in the brain [53]. 
If one includes GABAARs that can be classified as “tenta-
tive”  or  “existence  with  high  probability”,  the  number  of 
receptor combinations increases to 26 [53]. Preferred subunit 
combinations  are  specifically  distributed  among  different 
brain regions [69] and even demonstrate different subcellular 
localization [reviewed in 47]. Because each type of GAB-
AAR exhibits distinct biophysical and pharmacologic proper-
ties,  these  receptors  are  capable  of  diverse  influences  on 
regulating synaptic transmission and synaptic integration and 
since these receptors are expressed in parts of the nervous 
system which process higher-order brain functions, it is not 
surprising  that  GABAAR  function  is  central  to  memory, 
awareness and consciousness.  
ANESTHETIC ACTION ON NATIVE RECEPTORS 
  Anesthetic drugs allosterically modulate GABAARs and 
disrupt  normal  physiologic  circuits  which  require  precise 
timing of GABA-ergic  input.  There  exists strong evidence 
that GABAARs are involved in mediating some of the classi-
cal components of general anesthesia: hypnosis [2], depres-
sion of spinal reflexes [13], and amnesia [43]. The contribu-
tion of GABAARs in mediating immobility and analgesia is 
less clear (see mutagenesis section). Through experimental 
investigation it is becoming increasingly clear that not only 
are the different classical components of general anesthesia 
mediated by different pathways in the nervous system, but 
different  classes  of  anesthetics  can  have  differing  effects 
within these pathways.  
  For  example,  specific  behavioral  effects  by  pharma-
cologic therapeutics have been linked to different GABAAR 
assemblies present in different brain regions; sedation pro-
duced by benzodiazepines has been associated with the α1 
containing GABAARs [44] and anxiolysis appears to medi-
ated by α2 containing GABAARs in the limbic system but 
not the GABAARs in the reticular activating system; which 
primarily consists of α3 containing GABAARs [42].  
  Moreover,  manipulation  of  hippocampal  GABAARs  by 
the selective  intrasynaptic GABAAR blocker, gabazine, re-
vealed  that  isoflurane  selectively  enhances  intrasynaptic 
GABAA m ediated  currents  (associated  with  α1  –2,  β2  –3, 
and γ2 subunits) in comparison to thiopental which is less 
selective and augmented both intrasynaptic and extrasynaptic 
(via the α5 subunit) GABAA mediated currents [9]. Not only 
can anesthetics of different classes be selective in their neu-
rophysiological effects, but so can drugs of the same class, 
for example, synaptic input (frequency and decay time con-
stant) onto hippocampal interneurons is differentially modu-
lated by sevoflurane versus isoflurane [52]. From this hand-
ful of examples,  it  is clear that  the anesthetized state pro-
duced by each anesthetic is subtly unique and dependent on 
each  drug’s  particular  pharmacological  characteristics  in 
different brain regions. These microscopic observations are 
supported  by  autoradiographical  measurements  of  cerebral 
blood  flow  and  glucose  utilization  in  anesthetized  rodent 
brains which revealed that specific brain structures could be 
either  hypometabolic  or  hypermetabolic  depending  on 
whether isoflurane or sevoflurane were used [41]. However, 
the specific effect of each individual volatile anesthetic on 
specific GABAAR subunit assemblies has yet to be system-
atically examined. 
VOLATILE ANESTHETICS 
  Nakahiro et al. [49] were the first to directly record the 
enhancement  of  GABA  responses  by  isoflurane.  By  patch 
clamping  dorsal  root  ganglion  neurons  in  primary  culture, 
they were able to enhance the amplitude of currents activated 
by low concentrations of GABA. Our understanding of the 
molecular pharmacology of this anesthetic was further en-
hanced  when  it  was  shown  that  the  stereoselectivity  for 
GABAAR  modulation  paralleled  its  selectivity  as  an  anes-
thetic [21], strongly implicating the GABAAR as a critical 
target  site  for  isoflurane.  However,  our  understanding  of 
which  receptor  subunits  are  critical  for  general  anesthetic 
action remains incomplete, despite an enormous effort over 
the last 15 years using the appropriate concentrations of drug 
(the EC50s for general anesthesia translate to the following 
micromolar concentrations that should be used for in vitro 
experiments  at room temperature: 280 µM  isoflurane, 330 
µM, sevoflurane, 280 µM desflurane [18]) on recombinant 
receptors  in  heterologous  expression  systems  [22]  and  
cells that express unique GABAAR isoforms. But in general, 
what appears to be clear is as follows: isoflurane, desflurane 
and sevoflurane all  enhance  the amplitude of responses to 
low  concentrations  of  GABA  and  prolong  the  duration  
of  GABA  mediated  synaptic  inhibition.  At  supraclinical  
concentrations,  they  are  able  to  open  the  receptor’s  anion 
channel in the absence of GABA, a process known as “direct 
activation”.  
  All GABAARs containing an α subunit are sensitive to at 
least  one  volatile  general  anesthetic  drug.  The  co-
transfection of HEK293 cells with β1 subunit cDNAs with 
either an α1 or an α2 subunit cDNA is sufficient for the ex-
pression of GABAA Rs that are sensitive to isoflurane [22]. 
The addition of the γ subunit does not abolish isoflurane sen-
sitivity, thus we can safely conclude that the binding site(s) 
for inhaled anesthetics are located, at the very least, within 
alpha  and  beta  subunits.  This  is  in  contrast  to  homomeric 
receptors that are constructed from rho subunits and whose 
responses are inhibited by volatile anesthetics [45].  
  Research  on  the  effects  of  volatiles  at  extrasynaptic 
GABAARs in thalamic [8] and hippocampal [4] brain slice 
preparations  suggest  that  the  extrasynaptic  GABAARs  ex-
hibit higher affinities for GABA and exhibit decreased de-
sensitization. At present, there is great interest in the rele-
vance of extrasynaptic receptors in generating the anesthe-
tized state, with many laboratories investigating the impor-
tance of the anesthetic enhancement of CSF-activated tonic 
responses  that  are  associated  with  extrasynaptic  sites  (re-
viewed in [6]). According to our own measurements,  CSF 
contains ~150 nM GABA (A.J & P.S.G., data not shown). 
The resulting anion shunt is currently thought to be critical to 
the behavior of neurons in different brain regions. Similarly, 
the molecular actions of inhaled anesthetics on recombinant 
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thought to be associated with these extrasynaptic receptors 
are also being intensively investigated. Recent results in our 
laboratory  using  HEK293  cells  expressing  either  α1β2γ2s, 
α5β2γ2s, or α6β2γ2s GABAARs have demonstrated that each 
of these subunit combinations exhibits enhanced GABA sen-
sitivity with isoflurane in a dose-dependent fashion, but the 
α5- and α6- containing subunit combinations had a height-
ened GABA sensitivity and the α6β2γ2s combination dem-
onstrated  decreased  desensitization,  together  with  modest 
differences in isoflurane induced enhancement (see Table 1 
and Fig. 1). Evidence such as this effectively closes the loop 
on the hypotheses of extrasynaptic GABA-ergic transmission 
garnered in brain slice preparations. Our data is consistent 
with the observation that low, sub-anesthetic concentrations 
of  isoflurane  potentiate  the  Cl
-  current  at  α5β3γ2L  GAB-
AARs but not at α1β3γ2L GABAARs in hippocampal neurons 
[11]. It is important to recognize that dose can play an im-
portant  role  in  characterizing  the  effects  of  anesthetics  on 
these  receptors,  either  alone  or  in  combination  with  other 
anesthetics  because  drug  interactions  vary  considerably  at 
different  time  points  during  surgery  and  along  a  response 
surface [59]. Similarly, we feel that systematic investigations 
of drug actions on subunit combinations provides a clearer 
picture as to the effects of those drugs even if some of those 
subunit  combinations  have  not  been  identified  yet  in  the 
mammalian CNS. As it stands today, the literature is lacking 
a complete survey of the effect of isoflurane, sevoflurane and 
desflurane on the 26 GABAAR populations found in the CNS 
of a single species, using comparable methodologies, be it 
the kinetics of ion channel function or shifts of the GABA 
concentration response.  
  Desflurane and sevoflurane are both known to have simi-
lar actions on GABAARs as isoflurane; both drugs increase 
the apparent affinity of  the receptor for GABA. However, 
much less is known about their relative effects on different 
GABAA R subunits. Synaptic receptors containing α1, α2, 
β1 and β2 containing receptors are sensitive to at least one of 
these drugs, but their relative effects on extrasynaptic recep-
tors has yet to be studied [28, 51, 59].  
  Finally,  there  has  yet  to  be  published  an  unambiguous 
demonstration  of  volatile  anesthetic  action  on  GABAARs  
at  the single channel  level.  While  many studies using fast 
solution exchange have inferred that volatile anesthetics alter 
one or more rate constants that govern channel function [31], 
the  drug  effects  on  the  lifetimes  of  specific  states  remain 
unknown.  
INTRAVENOUS ANESTHETICS  
  In common with the inhaled anesthetics, the intravenous 
anesthetics (thiopental, etomidate and propofol) enhance the 
amplitude of responses to low concentrations of GABA at 
clinically  relevant  concentrations  (2  µM  propofol,  3  µM 
etomidate, 25 µM thiopental and 10 µM methohexital) and 
prolong the duration of GABA mediated synaptic inhibition. 
At  supraclinical  concentrations,  they  also  directly  activate 
the receptor’s anion channel.  
  The interactions between GABAARs and the intravenous 
anesthetics are generally thought to occur within, or proxi-
mal to, the β subunits. Since the β subunit shows less spe-
cific subcellular localization than that of the α subunit, the 
intravenous  anesthetics  may  not  demonstrate  rich  physio-
logical differences among intra- vs extra-synaptic GABAARs 
throughout the brain. Additionally, the distribution of the β 
subunit in mammalian brain does not share the same clear 
distinctions as the distribution of the α subunit[40, 69]. By 
examining  in  situ  hybridization  data,  one  clear  trend 
emerges: the β1 subunit is largely confined to the hippocam-
pus while the β2 and β3 subunits appear more widely dis-
tributed.  
Propofol 
  The  dialkylphenol,  propofol  (2,6,  diisopropylphenol) 
potentiates GABA responses and directly activates GABAAR 
function [55]. Initially, only the property of direct activation 
of the GABA receptor by propofol was assumed to be de-
pendent on the β subunit [55, 56] while the modulatory ef-
fects were considered to involve other subunits [56]. There is 
evidence that α, β and γ subunits all contribute to GABAAR 
sensitivity  to propofol [20, 32, 39]. In particular, propofol 
was shown to be less efficacious at β1 containing receptors 
than at those containing β2 or β3 subunits [57]. The potency 
and the efficacy of the receptor – drug interaction is depend-
ent  on  key  propofol  moieties,  most  notably,  the  phenolic 
hydroxyl group and the number and arrangement of methyl 
groups at the 2- and 6- positions that flank it [37]. Interest-
ingly this study indicated that the 4-position played little role 
in modulation. The discovery of the essential pharmacophore 
for propofol’s action, it has recently led to the development 
of FOS-propofol, a new anesthetic that releases a propofol 
molecule after liver metabolism. This provides the anesthe-
siologist with a water soluble anesthetic that has slower in-
duction kinetics  than  it’s  active  metabolite, which may be 
desirable in some surgical settings [48].  
Table 1.   
  Isoflurane 140 µM  Isoflurane 280 µM  Isoflurane 560 µM  Isoflurane 1400 µM 
α1β2γ2s  0.35 ± 0.06  0.54 ± 0.06  0.56 ± 0.02  0.58 ± 0.03 
α5β2γ2s  0.28 ± 0.05  0.54 ± 0.03  0.57 ± 0.05  0.75 ± 0.03 
α6β2γ2s  0.44 ± 0.09  0.57 ± 0.12  n.d.  0.60 ± 0.08 
Fractional Effect of Isoflurane on GABA EC50 for α1β2γ2s, α5β2γ2s, and α6β2γ2s GABAA receptors. Values are mean ± SEM and are determinations of at least 4 concentration-
response shifts from at least 3 cells, as determined by the fractional change in the effective GABA concentration for 50% of maximal activation (EC50). Isoflurane concentrations are 
reported as molar concentrations. These concentrations equate to 0.5, 1, 2 and 5 times isoflurane minimum alveolar concentration (MAC). n.d. (not determined). 6    Current Neuropharmacology, 2010, Vol. 8, No. 1  Garcia et al. 
  Finally,  propofol  may  be  actively  involved  in  the  re-
cruitment of new subunits to the surface of the neuron; quan-
titative PCR revealed that during deep anesthesia propofol, 
increases  α4  subunit  mRNA  occurred  in  comparison  with 
midazolam, thiopental and isoflurane [60].  
Etomidate 
  The effects of etomidate on GABA and benzodiazepine 
binding at the GABAAR have been known for over 25 years 
[65]. Like isoflurane, etomidate interacts with the GABAAR 
in a stereospecific manner [67]. Etomidate has smaller ef-
fects on receptors containing the β1 subunit [24]. Of all of 
the  clinically  used  anesthetics,  etomidate  has  the  greatest 
selectivity  for  the  GABAAR,  and  has  the  fewest  relevant 
interactions with other ion channels in order to generate the 
anesthetized state.  
Thiopental 
  Besides methohexital which has a special role in electro-
convulsive  therapy  [26],  thiopental  is  the  only  barbiturate 
routinely used by modern anesthesiologists. Like etomidate, 
it is known to enhance GABAAR function in a stereospecific 
manner [68]. This is also true for other barbiturate sedatives 
such  as  hexabarbital  and  pentobarbitial.  The  action  of  the 
latter drug has been confirmed at the single channel level, in 
what is arguably the most detailed study of a general anes-
thetic  modulating  the  GABAAR.  Steinbach  and  Akk  [63] 
demonstrated  the  complexity  of  the  anesthetic-receptor 
modulation, but were also able to clearly show that pento-
barbital enhanced channel function by stabilizing one of the 
open states. In common with high concentrations of propofol 
and etomidate, thiopental can also directly gate GABAARs.  
  Thiopental appears to be selective for either tonic or pha-
sic GABAAR activity in the hippocampus [9] suggesting a 
possible role for the δ subunit in controlling thiopental ac-
tions on GABAARs. This is interesting since the molecular 
site  of  action  of  barbiturates  at  GABAARs  has  long  been 
thought to reside within one of the β subunits. Thus, it would 
appear that barbiturate actions on GABAARs are more com-
plex  than  with  other  anesthetics  [63].  This  observation  is 
supported by the fact that thiopental is a more effective ago-
nist than GABA in receptors containing α6 subunits [14].  
MUTANT  RECEPTORS  AND  GENETICALLY  
MANIPULATED ANIMALS 
  In 1997, Neil Harrison and Adron Harris published the 
















Fig. (1). Examples of chloride currents for α1β2γ2s, α5β2γ2s, and α6β2γ2s GABAA receptors. Left panels show representative whole-cell re-
cordings achieved by applications of increasing concentrations of GABA (black bars). Right panels show paired recordings with the same 
concentrations of GABA in the presence of 2 MAC isoflurane (blue bar). GABA concentrations (all in µM) for α1β2γ2s GABAA receptors 
(0.3, 1, 3, 10, 30, 100, 300, 1000), for α5β2γ2s GABAA receptors (0.1, 0.3, 1, 3, 10, 30, 100, 300), and for α6β2γ2s GABAA receptors (0.1, 
0.3, 1, 3, 10, 30, 100). Vertical scale bars 100 pA; Horizontal scale bars 10 s. The data indicate that α6 containing receptors are more sensi-
tive to low concentrations of anesthetic than α1β2γ2s, or α5β2γ2s receptors and that isoflurane is more effective at reducing the apparent affin-
ity of GABA at α5 containing receptors than at α1β2γ2s, or α6β2γ2s GABAA receptors. The methods used to collect these results have been 
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sitive  to inhaled anesthetics [46]. The rationale behind the 
ground-breaking work was similar to the successful strategy 
that had revealed the functional target site of benzodiazepi-
nes 4 years earlier [35], taking advantage of the fact that the 
function of receptors constructed from the ρ1 subunit was 
not enhanced by inhaled anesthetics [45]. Through a series of 
receptor chimeras, they identified a pair of transmembrane 
amino acid substitutions that were sufficient to render α2β1 
containing receptors insensitive to enflurane, an inhalational 
anesthetic (and a chemical isomer of isoflurane). By replac-
ing the α2 residues serine270 and alanine291 with the corre-
sponding  residues  in  the  rho1  subunit,  an  isoleucine  and 
tryptophan respectively, the recombinant receptors were no 
longer enhanced by the anesthetic. One week later,  it was 
reported  that a homologous residue in  the β3 subunit was 
critical for the action of intravenous anesthetics [7].  
  During the following decade, mutations have been intro-
duced  into  many  of  the  GABAAR  subunit  transmembrane 
domains, using a variety of rationales, to delineate the gen-
eral anesthetic target sites in each receptor subunit (see Table 
2). In all cases, the mutation of one or more transmembrane 
residues has resulted in the impairment or abolition of anes-
thetic modulation by either isoflurane, desflurane, sevoflu-
rane, propofol or etomidate. Each of these studies concluded 
that amino acid substitutions alter the molecular environment 
in the anesthetic binding cavity, presumably by reducing the 
number of favorable interactions between  the receptor and 
the anesthetic  molecule and thus reduced  the effect of the 
anesthetic on enhancing GABAAR function. In common with 
the work with the different subunit combinations, our under-
standing of the specific residue-anesthetic interactions is also 
far from complete.  
  For the inhaled anesthetics, the majority of the published 
studies have focused on the interactions of isoflurane with 
mutant  receptors  and  in  comparison,  much  less  is  know 
about the interaction of sevoflurane and desflurane with mu-
tant receptors. That said, where comparisons are possible, it 
appears that all three inhaled anesthetics behave in qualita-
tively similar manners, but it is premature to say for certain 
whether  all  inhaled  anesthetics  interact  with  their  binding 
sites identically. Only a complete survey of all the critical 
positions in all of the subunits will reveal if inhaled anesthet-
ics  preferentially  target  specific  parts  of  a  given  receptor 
population. But at the current time, it is fair to say that these 
three anesthetics likely form weak bonds with several resi-
dues  in  the  four  transmembrane  domains  of  GABAAR  α 
subunits as their primary interaction with their critical neu-
ronal targets.  
  For many years, a slightly clearer picture emerged for the 
intravenous anesthetics  interacting with β subunits,  in part 
due to the relative ease of conducting experiments with non-
volatile compounds, the smaller number of β subunits and 
the smaller number of IV anesthetics. Again, residues in the 
4 transmembrane domains appear to be critical in defining 
the actions of etomidate, propofol and barbiturates.  
  It is interesting to note that the mutation of many residues 
in the transmembrane domains have modest effects on anes-
thetic modulation of GABAARs. However, the strongest ef-
fects seem to be reserved for homologous positions in trans-
membrane domains M2, M3 and M4 respectively (see Table 
2) and there is evidence to suggest that this pattern extends 
across several members of the LGIC superfamily [36].  
  The full potential of these studies was realized in 2003 
and again in 2005 when the first reports of the incorporation 
of some of these mutations into the mouse genome were re-
ported [25, 34]; the mouse lines generated exhibited a selec-
tive loss of sensitivity to intravenous and inhaled anesthetics 
respectively.  These  animals  and  their  lines  that  they  have 
inspired [10, 16, 70-72] are now being used extensively to 
understand the role different GABAAR subunits are playing 
in generating the anesthetized state.  
CONCLUSIONS 
  Our current understanding of the molecular mechanisms 
of general anesthesia will not be complete until we under-
stand how drug action at multiple sites alters the integration 
of information in the nervous system. Central to this will be 
an understanding of which circuits in the nervous system are 
most important for generating sensation and how perturba-
tions at receptors  in these circuits generates a state of an-
aisthesis. We have already seen how GABA receptor modu-
lation leads to the sleep-like state associated with anesthesia 
[50].  Using  the  knowledge  derived  from  the  studies  de-
Table 2.    
Transmembrane Domain 
Subunit  M1  M2  M3  M4 
α1  [5]  [25]  [33]  [27] 
α2  [29]  [46]  [46]  - 
α3  -  [58]  [58]  - 
β1  [19]  [66]  -  - 
β2  [12]  [7]  [38]  [54] 
Transmembrane domain mutations in most of the synaptic GABAA receptor subunits reduce modulation by general anesthetics. M1 denotes transmembrane domain number 1. Refer-
ences are from a mixture of species, comprising human, rat and mouse gene products. A dash denotes that to our knowledge, the domain has not yet been mutated to render a signifi-
cant effect on the effect of a clinically used anesthetic. 8    Current Neuropharmacology, 2010, Vol. 8, No. 1  Garcia et al. 
scribed here, we should  learn in  the  coming years  a great 
deal more about the molecular mechanisms of sleep, sensa-
tion, pain and perhaps one day, consciousness.  
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